Aspirin Use in Primary Prevention: New Insights for Patients with Type 2 Diabetes
Introduction to Aspirin’s Role
The medical community has long pursued the optimal balance of aspirin in primary prevention strategies. Recent findings from the American Heart Association (AHA) Scientific Sessions 2025 present a compelling opportunity for a specific cohort of patients—those diagnosed with Type 2 Diabetes (T2D) and categorized as having moderate-to-high cardiovascular risk—to enhance their health outcomes through regular aspirin intake.
Primary Prevention Outcomes: A Clear Benefit
A thorough analysis involving over 11,000 patients has demonstrated notable reductions in adverse clinical events for individuals using aspirin (ASA) compared to those who did not. Over a decade-long study period, the cumulative incidence of heart attacks (MI) was significantly lower in the ASA group, recorded at 42.4% versus 61.2% in the non-ASA group.